LncRNAs and MiRNAs: New Targets for Resveratrol in Ovarian Cancer Research

被引:2
作者
Chaichian, Shahla [1 ]
Bidgoli, Sepideh Arbabi [2 ]
Nikfar, Banafsheh [1 ]
Moazzami, Bahram [1 ]
机构
[1] Iran Univ Med Sci, Pars Hosp, Pars Adv & Minimally Invas Med Manners Res Ctr, Tehran, Iran
[2] Tehran Med Sci Univ, Islamic Azad Univ, Fac Pharm & Pharmaceut Sci, Dept Toxicol & Pharmacol, Tehran, Iran
关键词
Ovarian cancer; lncRNAs; epigenetic; gynecological cancers; resveratrol; angiogenesis; BETA SIGNALING PATHWAY; NONCODING RNA; UP-REGULATION; PROMOTES APOPTOSIS; CELL-PROLIFERATION; ASSOCIATION; RISK; POLYMORPHISM; MIGRATION; BREAST;
D O I
10.2174/1389201024666221111160407
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ovarian cancer (OC) is the 3(rd) common gynecologic cancer. Numerous procedures are involved in the growth of OC, like migration, angiogenesis, proliferation, apoptosis, invasion, and metastasis. Therefore, a better knowledge of the molecular processes complicated in ovarian tumorigenesis can lead to better measures for the prevention and treatment of the disease and its diagnosis. Long non-coding RNAs (LncRNAs), a subclass of non-coding RNAs, are much more diverse than previously thought. It is suggested that these RNAs may play a role in controlling complex cellular signaling mechanisms via binding to proteins and influencing their function. Nevertheless, our acquaintance with the participation of LncRNAs in the pathogenesis of OC is still restricted. Especially, we do not yet recognize how to pharmacologically correct the epi-mutations. Resveratrol, a natural polyphenol mostly derived from grapes, has been evaluated in many studies to find its cancer therapeutic potential. In the current paper, we aimed to review the role of resveratrol as a potential natural product on lncRNAs as novel diagnostic and therapeutic targets in OC and represent new insights for further investigations.
引用
收藏
页码:3238 / 3248
页数:11
相关论文
共 85 条
[1]  
Aggarwal BB, 2004, ANTICANCER RES, V24, P2783
[2]   Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms [J].
Arcidiacono, Biagio ;
Iiritano, Stefania ;
Nocera, Aurora ;
Possidente, Katiuscia ;
Nevolo, Maria T. ;
Ventura, Valeria ;
Foti, Daniela ;
Chiefari, Eusebio ;
Brunetti, Antonio .
EXPERIMENTAL DIABETES RESEARCH, 2012,
[3]   Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway [J].
Bai, Lin ;
Wang, Aihua ;
Zhang, Yali ;
Xu, Xiaofeng ;
Zhang, Xiao .
EXPERIMENTAL CELL RESEARCH, 2018, 366 (02) :161-171
[4]   Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis [J].
Barry, John A. ;
Azizia, Mallika M. ;
Hardiman, Paul J. .
HUMAN REPRODUCTION UPDATE, 2014, 20 (05) :748-758
[5]   Long Non-Coding RNA HOTAIR in Breast Cancer Therapy [J].
Cantile, Monica ;
Di Bonito, Maurizio ;
Cerrone, Margherita ;
Collina, Francesca ;
De Laurentiis, Michelino ;
Botti, Gerardo .
CANCERS, 2020, 12 (05)
[6]   A potential novel treatment strategy: inhibition of angiogenesis and inflammation by resveratrol for regression of endometriosis in an experimental rat model [J].
Cenksoy, Pinar Ozcan ;
Oktem, Mesut ;
Erdem, Ozlem ;
Karakaya, Cengiz ;
Cenksoy, Cahit ;
Erdem, Ahmet ;
Guner, Haldun ;
Karabacak, Onur .
GYNECOLOGICAL ENDOCRINOLOGY, 2015, 31 (03) :219-224
[7]  
Chen CL, 2000, CLIN CANCER RES, V6, P474
[8]  
Chen SS, 2015, INT J CLIN EXP MED, V8, P10845
[9]   Antisense COOLAIR mediates the coordinated switching of chromatin states at FLC during vernalization [J].
Csorba, Tibor ;
Questa, Julia I. ;
Sun, Qianwen ;
Dean, Caroline .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (45) :16160-16165
[10]   Progesterone action in breast, uterine, and ovarian cancers [J].
Diep, Caroline H. ;
Daniel, Andrea R. ;
Mauro, Laura J. ;
Knutson, Todd P. ;
Lange, Carol A. .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2015, 54 (02) :R31-R53